If we want to go beyond the proteasome inhibitors, IMiDs and anti-CD38 antibodies in multiple myeloma, there are plenty of emerging candidates these days.
This is excellent news, but how will it all fit together, and which gems were under-rated at the recent ASH meeting?
The latter may catch a few people by surprise when the clinical aspects are considered in the totality of what needs to be done and in which patient subsets.
We discuss near and medium term aspects, which may have a lasting impact and also talk about why they matter.
To find out, the final part of our myeloma mini-series offers an engaging and thoughtful fireside chat with a global thought leader in this niche…